Cargando…
Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease
This commentary provides an overview of the putamen as an established target site for gene therapy in treating aromatic l‐amino acid decarboxylase (AADC) deficiency and Parkinson’s disease, two debilitating neurological disorders that involve motor dysfunction caused by dopamine deficiencies. The ne...
Autores principales: | Hwu, Paul Wuh‐Liang, Kiening, Karl, Anselm, Irina, Compton, David R, Nakajima, Takeshi, Opladen, Thomas, Pearl, Phillip L, Roubertie, Agathe, Roujeau, Thomas, Muramatsu, Shin‐ichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422070/ https://www.ncbi.nlm.nih.gov/pubmed/34423905 http://dx.doi.org/10.15252/emmm.202114712 |
Ejemplares similares
-
Depletion of AADC activity in caudate nucleus and putamen of Parkinson’s disease patients; implications for ongoing AAV2-AADC gene therapy trial
por: Ciesielska, Agnieszka, et al.
Publicado: (2017) -
Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency
por: Tai, Chun-Hwei, et al.
Publicado: (2022) -
Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency
por: Wassenberg, Tessa, et al.
Publicado: (2017) -
Long-Term Outcomes of Eladocagene Exuparvovec Compared with Standard of Care in Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency: A Modelling Study
por: Simons, Claire L., et al.
Publicado: (2023) -
Compound Heterozygosis in AADC Deficiency and Its Complex Phenotype in Terms of AADC Protein Population
por: Bisello, Giovanni, et al.
Publicado: (2022)